A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505576-29-00

Acronym

LB101-101

Enrollment

Registered

2023-11-20

Start date

2024-01-03

Completion date

2024-11-21

Last updated

2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026